Valuation: Ono Pharmaceutical Co., Ltd.

Market Cap 1,140B 7.02B 6.13B 5.66B 5.22B 9.83B 676B 10.05B 67.66B 26.61B 331B 26.36B 25.78B P/E 2027 *
16.1x
P/E 2028 * 18.2x
Enterprise Value 941B 5.79B 5.06B 4.67B 4.31B 8.12B 558B 8.3B 55.84B 21.96B 273B 21.76B 21.28B EV / Sales 2027 *
2.07x
EV / Sales 2028 * 2.07x
Free-Float
80.98%
Yield 2027 *
3.23%
Yield 2028 * 3.2%
06-19 Mizuho Securities Upgrades Ono Pharmaceutical to Buy from Neutral; Price Target is 3,200 Yen MT
06-18 Ono Pharmaceutical to Dispose of 47 Million Yen Treasury Shares Under Stock Compensation Plan MT
06-01 Ono Pharmaceutical Co., Ltd. Announces Oral Presentation Of New Data From The Phase 2 Clinical Study Of ONO-4578 In Certain Gastric Cancers At The ASCO 2026 Annual Meeting CI
05-29 Jefferies Adjusts Ono Pharmaceutical's Price Target to 2,500 Yen From 1,750 Yen, Keeps at Hold MT
05-08 Ono Pharmaceutical's Attributable Profit Jumps 39% in Fiscal Year 2025 MT
05-07 Ono Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended March 31, 2026 CI
05-07 Ono Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2027 CI
05-07 Ono Pharmaceutical Co., Ltd. Proposes Year End Dividend for the Fiscal Year Ended March 31, 2026, Payable on June 19, 2026 and Provides Dividend Forecasts for the Second Quarter of Year Ending March 31, 2027 and Fiscal Year Ending March 31, 2027 CI
04-22 Top Midday Stories: GE Vernova Shares Gain on Strong Q1 Earnings, Guidance; Vertiv Lifts Guidance After Q1 EPS, Revenue Beats, Shares Fall MT
04-22 Merck, Rivals Show Interest in Inhibrx's Experimental Cancer Drug MT
04-22 Merck, Rivals Show Interest in Inhibrx's Experimental Cancer Drug MT
04-22 Merck, Rivals Show Interest in Inhibrx's Experimental Cancer Drug MT
04-22 Merck, rivals eye Inhibrx experimental cancer drug tied to Keytruda, sources say RE
1 day+3.37%
1 week-0.96%
Current month+1.57%
1 month+7.37%
3 months-2.67%
6 months+7.30%
Current year+11.65%
1 week 2,344.5
Extreme 2344.5
2,451
1 month 2,208
Extreme 2208
2,507
Current year 2,114.5
Extreme 2114.5
2,674.5
1 year 1,579.5
Extreme 1579.5
2,674.5
3 years 1,474
Extreme 1474
2,966.5
5 years 1,474
Extreme 1474
3,990
10 years 1,474
Extreme 1474
4,107
Manager TitleAgeSince
Chief Executive Officer 67 2024-03-31
Director of Finance/CFO - 2026-03-31
President 57 2024-03-31
Director TitleAgeSince
Chairman 67 2024-03-31
Director/Board Member 57 2020-05-31
Director/Board Member 76 2018-06-25
Change 5-day change 1-year change 3-year change Capi.($)
+3.37%-0.96%+46.11%-4.38% 6.79B
-0.90%-0.31%+13.62%+80.12% 48.56B
-0.23%-0.63%+67.00%+115.81% 35.65B
-0.76%-1.57%-3.87%+37.62% 11.98B
-0.88%-1.32%+18.04%+92.11% 11.95B
+1.12%+1.90%+34.67%+129.06% 9.29B
-0.75%-0.91%+18.26%+37.23% 6.95B
-2.25%-1.40%+1.39%+218.40% 6.7B
-9.93%+5.82%-22.89%+16.29% 6.81B
-0.97%+3.38%+22.66%+136.78% 4.48B
Average -1.22%+0.95%+19.50%+85.90% 14.91B
Weighted average by Cap. -0.87%+0.45%+26.39%+88.40%

Financials

2027 *2028 *
Net sales 454B 2.8B 2.45B 2.26B 2.08B 3.92B 269B 4.01B 26.97B 10.61B 132B 10.51B 10.28B 444B 2.74B 2.39B 2.21B 2.03B 3.84B 264B 3.92B 26.39B 10.38B 129B 10.28B 10.06B
Net income 70.97B 437M 382M 352M 325M 612M 42.1B 626M 4.21B 1.66B 20.62B 1.64B 1.61B 62.51B 385M 336M 310M 286M 539M 37.08B 551M 3.71B 1.46B 18.16B 1.45B 1.41B
Net Debt -199B -1.23B -1.07B -989M -912M -1.72B -118B -1.76B -11.83B -4.65B -57.87B -4.61B -4.51B -218B -1.34B -1.17B -1.08B -999M -1.88B -129B -1.92B -12.96B -5.1B -63.39B -5.05B -4.94B
Logo Ono Pharmaceutical Co., Ltd.
Ono Pharmaceutical Co Ltd is a Japan-based company primarily engaged in the pharmaceutical business. The Company is engaged in the manufacture and sale of prescription and over-the-counter drugs. The Company has been particularly focused on research and development of prescription drugs, positioning them as its core business. The Company’s products include injectables, oral medications, and patches.
Employees
4,206
Date Price Change Volume
26-07-17 JP¥2,425.50 +3.37% 2,057,200
26-07-16 JP¥2,346.50 -1.76% 1,579,900
26-07-15 JP¥2,388.50 -1.81% 1,516,100
26-07-14 JP¥2,432.50 +1.33% 1,327,200
26-07-13 JP¥2,400.50 -1.13% 1,072,800
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
12
Last Close Price
2,425.50JPY
Average target price
2,500.00JPY
Spread / Average Target
+3.07%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 4528 Stock